Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Pancreatic Neoplasms 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Breast Neoplasms 3Ovarian Neoplasms 2Multiple Myeloma 2Lung Neoplasms 2Hematologic Neoplasms 2Wilms Tumor 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, Non-Hodgkin 1

Interventions

Gemcitabine 9pembrolizumab 7Cisplatin 5enfortumab vedotin 4atezolizumab 4Trastuzumab 4Mitomycin 4Carboplatin 4Sunitinib 3Pemetrexed 3dodecyl maltoside 2cabozantinib 2Water 2Sugammadex 2Standard of Care 2Saline Solution 2Paclitaxel 2Nivolumab 2Neostigmine 2Docetaxel 2Cetuximab 2Bevacizumab 2zidovudine 5'-monophosphate-mannose-albumin conjugate 1vinflunine 1valrubicin 1tucatinib 1tislelizumab 1testosterone 17 beta-cypionate 1temsirolimus 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urologic Neoplasms × Ado-Trastuzumab Emtansine × Genitourinary × Clear all
NCT02675829 2026-03-04

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
131 enrolled
GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡